Pfizer India has reportedly become the first pharmaceutical firm to approach the Drugs Controller General of India (DCGI) to seek emergency use authorisation for its Covid-19 vaccine in the country.
The application was submitted by Pfizer India on December 4 to the DCGI seeking emergency use authorization (EUA), for grant of permission to import and market Pfizer-BioNTech’s Covid-19 vaccine in India.
The extremely low temperature of minus 70 degrees Celsius, required for storing the vaccine poses a big challenge for its delivery in a country like India.
On December 2, the UK became the first country to approve the Pfizer/BioNTech coronavirus vaccine, with the country’s regulator granting temporary authorisation for the emergency use of coronavirus vaccine. Bahrain on Friday also granted permission for the two-dose vaccine made by Pfizer and its German partner BioNTech.
At an all-party meeting last week, Prime Minister Narendra Modi said an Indian Covid-19 vaccine is expected to be ready by January, and as soon as scientists give a green signal, vaccination will start in India.
- Sikkim logs 40 new COVID-19 cases, 1 fresh fatality
- Fixed-wing flight services to remote towns of Arunachal Pradesh
- PM urges people to ensure no one is left out of vaccination’s ‘circle of safety’
- Sikkim districts to undergo nomenclature change: CM Golay
- How this social entrepreneur is championing love for voiceless animals
- Assam: 5 of 6 accused deny charges of instigating Gorukhuti violence